News - Appointments

Jens-Peter Marschner, a medical doctor and expert in drug development, has joined Zelluna Immunotherapy AS as chief medical officer to help advance the company’s lead T cell receptor product into the clinic.

Biotech entrepreneur Jonathan Montagu has joined the board of OMass Therapeutics Ltd as a non-executive director to help guide the company’s drug discovery activities. Founded in 2016, OMass uses structural mass spectrometry to discover new drug compounds.

John Haurum, formerly chief executive of F-star Biotechnology Ltd, has been appointed to the board of Storm Therapeutics Ltd as an independent non-executive director. Storm is focused on the discovery of small molecule therapies that modulate RNA epigenetics.

Adrian Rawcliffe has been promoted to the position of chief executive of Adaptimmune Therapeutics Plc, succeeding co-founder James Noble who will retire on 1 September. Mr Rawcliffe has been chief financial officer since 2015 when he joined Adaptimmune from GlaxoSmithKline Plc.

Dr Thomas Kleen, a specialist in designing immune monitoring technologies, has joined Immodulon Therapeutics Ltd in Uxbridge, England, as chief scientific officer.  He most recently served as an executive vice president for immune monitoring at Precision for Me

Roche Holdings Ltd is making a number of top-level changes as current executives retire or resign. Michael Heuer, chief executive of Roche Diagnostics and executive committee member, will retire at the end of July, having reached the age of 65.

Oxford BioDynamics Plc has hired Bartu Ahiska to lead the commercialisation of the UK company’s EpiSwitch, a platform for discovering and evaluating the type of epigenetic biomarkers known as ‘chromosome conformation signatures’ (CCSs).  He joins OBD from the K

Nanobiotix SA, a late-stage nanomedicine company, has appointed Edwina Baskin-Bey, a medical doctor, to replace Elsa Borghi, also a medical doctor, as chief medical officer. Dr Borghi will remain with Nanobiotix, focusing on early stage development.

The UK’s Northern Health Science Alliance, which promotes the interest of health research universities, NHS teaching trusts and academic health science networks across northern England, has appointed Seamus O’Neill as its chief executive office

Quell Therapeutics Ltd, recently formed to engineer regulatory T cells (Tregs) to overcome autoimmune and inflammatory diseases as well as immune dysfunction, has appointed Iain McGill as chief executive.